|
| Press Releases |
|
 |
|
| Tuesday, August 29, 2023 |
|
|
Malaysian Genomics Unveils Strategic Advances in Biopharmaceuticals |
| Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, recorded a revenue of RM2.23 million for the 4th quarter ended 30 June 2023. This represents a decrease from RM6.33 million in the corresponding quarter of the preceding year, owing to a deliberate pivot from vaccines to cell and gene therapy products, focusing more on genetic screening initiatives. more info >> |
|
| Monday, May 15, 2023 |
|
|
Malaysian Genomics Inks Agreement in Expansion to Bangladesh |
| Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced a strategic cooperation agreement (SCA) with Toticell Limited for the distribution of the Group's products in Bangladesh. more info >> |
|
| Monday, February 27, 2023 |
|
|
Malaysian Genomics to Boost Play on the Football Pitch |
| Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, is collaborating with KL City FC Sdn Bhd (KLCFC), the manager of the KL City FC football club, on the deployment of the Group's genetic screening tests for peak athletic performance. more info >> |
|
| Friday, February 24, 2023 |
|
|
Malaysian Genomics Pivots to Biopharmaceuticals for Growth |
| Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today announced that the Group recorded a revenue of RM1.64 million for the second quarter ended 31 December 2022 (2Q 2023). This amount is down from RM7.63 million in 2Q 2022, as the Group moved its focus from vaccines to biopharmaceuticals. more info >> |
|
|
Malaysian Genomics to Collaborate on Cannabinoid R&D |
| Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today announced that the Group has entered into a strategic collaboration with Kensana Health Canada and MAHSA University for the research and development (R&D) of phytopharmaceutical and biotechnology products that can lead to commercialisation. more info >> |
|
| Wednesday, February 22, 2023 |
|
|
Malaysian Genomics to Offer World's First DNA-Driven Fertility Test |
| Malaysian Genomics Resource Centre Bhd, a leading genomics and biopharmaceutical specialist, today announced that the Group has signed a strategic collaboration agreement with Divine Genes Sdn Bhd to collaborate on business opportunities in relation to the improvement and international distribution of genetic tests for reproductive health. more info >> |
|
| Monday, January 9, 2023 |
|
|
Malaysian Genomics Explores R&D Collaboration with SIRIM |
| Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce a strategic cooperation with SIRIM Berhad, to explore the commercialisation of joint research and development (R&D) projects in the medical and biotechnology fields. more info >> |
|
| Wednesday, November 23, 2022 |
|
|
Malaysian Genomics Sees Rise in Profit Margins for 1Q |
| Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today reported a revenue of RM3.81 million for the first quarter ended 30 September 2022 (1Q 2023) versus a revenue of RM9.32 million in 1Q 2022, as the Group refocuses on immunotherapy and cell therapies under the biopharmaceutical business and pushes for organic growth of its genetic screening business. more info >> |
|
| Wednesday, October 26, 2022 |
|
|
Malaysian Genomics Signs Strategic Collaboration Agreement for Expansion in the UAE |
| Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced the signing of a Strategic Collaboration Agreement (SCA) outlining partnerships to market and distribute the Group's Dtect(R) range of genetic screening services in the United Arab Emirates (UAE). more info >> |
|
| Wednesday, October 12, 2022 |
|
|
Malaysian Genomics Signs Agreement with National Institutes of Health to Explore Research Opportunities |
| MGRC Therapeutics Sdn Bhd (MGRC-T), a wholly-owned subsidiary of Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, has entered into a cooperation agreement with the National Institutes of Health, Malaysia (NIH), providing a framework for collaboration between the two parties in medical research pertaining to genomics and biopharmaceuticals. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
ARE Expands India Leadership, Strengthens Regional Role in Climate, Energy, and Food System Transition
Jun 13, 2025 12:46: JST
|
|
|
TRENDE Announces Strategic Capital and Business Alliance with Tokyu Land
Jun 13, 2025 13:00 JST
|
|
|
ARE Expands India Leadership, Strengthens Regional Role in Climate, Energy, and Food System Transition
Jun 13, 2025 11:46 HKT/SGT
|
|
|
JBM Healthcare Delivers Strong FY2025 Annual Results, Net Profit Surged 51.2% to HK$197.3 Million
Jun 12, 2025 21:07 HKT/SGT
|
|
|
健倍苗苗二零二五財年全年業績表現亮眼 純利飆升51.2%至1.97億港元
Jun 12, 2025 20:58 HKT/SGT
|
|
|
健倍苗苗二零二五财年全年业绩表现亮眼 纯利飙升51.2%至1.97亿港元
Jun 12, 2025 20:48 HKT/SGT
|
|
|
品質基石的守護者：檢測檢驗行業賦能高質量發展
Jun 12, 2025 18:28 HKT/SGT
|
|
|
质量基石的守护者：检测检验行业赋能高质量发展
Jun 12, 2025 18:19 HKT/SGT
|
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances
Jun 12, 2025 17:38: JST
|
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances
Jun 12, 2025 16:38 HKT/SGT
|
|
|
耐賦康(R)與EVER001協同發力 雲頂新耀推動腎病治療進入精準管理新階段
Jun 12, 2025 16:31 HKT/SGT
|
|
|
耐赋康(R)与EVER001协同发力 云顶新耀推动肾病治疗进入精准管理新阶段
Jun 12, 2025 16:26 HKT/SGT
|
|
|
10 winners selected at 8th edition of Start-up Express
Jun 12, 2025 12:29 HKT/SGT
|
|
|
LEGENDARY HUMANITY Announces Strategic Bitcoin Reserves and Enhancements to the VIVI Token Ecosystem
Jun 12, 2025 09:00: JST
|
|
|
LEGENDARY HUMANITY Announces Strategic Bitcoin Reserves and Enhancements to the VIVI Token Ecosystem
Jun 12, 2025 08:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
